GRI Bio, Inc. (ticker: GRI) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of GRI's SEC filings surfaces 2 active risk signals, including 2 auditor-change signals. GRI reported $0 in revenue and -$2.00M for the period ending 2022-03-31, with operating cash flow of -$3.69M. Cash and equivalents stood at $11.05M (up 236.7% year-over-year). Total assets of $11.34M exceed total liabilities of $794K. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
GRI Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for GRI Bio, Inc. (GRI) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.